News

Article

EMA Recommends Seven Medicines for Approval in October

Author(s):

The recommended medicines include treatments for Duchenne muscular dystrophy, relapsed or refractory multiple myeloma, hyperargininemia, invasive candidiasis, menopause symptoms, and diagnostic medicines for characterizing lesions.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

The European Medicines Agency (EMA) announced on Oct. 13, 2023 that the agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended seven new medicines for the treatment of a variety of conditions, including Duchenne muscular dystrophy, relapsed or refractory multiple myeloma, hyperargininemia, invasive candidiasis,menopause symptoms, and diagnostic medicines for characterizing lesions. EMA also announced two withdrawn marketing applications—for Jivadco and Sugammadex Lorien—and reexamination requests for Translarna and Blenrep. A review of the benefits and risks of Ocaliva (obeticholic acid), which treats adults with primary biliary cholangitis, was also initiated.

Among the positive opinions granted by CHMP is a treatment for Duchenne muscular dystrophy, Agamree (vamorolone), which is a genetic disorder with progressive loss of muscle function. Elrexfio (elranatamab) was approved for the treatment of adult patients with relapsed or refractory multiple myeloma, a rare cancer of the bone marrow.  A positive opinion under exceptional circumstances was granted to Loargys (pegzilarginase) for the treatment of a rare disease with neurological clinical signs, hyperargininemia. Rezzayo (rezafungin) was granted approval for the treatment of invasive candidiasis, a serious fungal infection caused by Candida. In addition, a treatment for moderate-to-severe hot flashes due to menopause—Veoza (fezolinetant)—was approved.

Two diagnostic medicines for the detection of central nervous system lesions—Elucirem (gadopiclenol) and Vueway—were also approved. CHMP also extended indications for Brukinsa, Imfinzi, Jemperli, Keytruda, Praluent, Prevymis, Rubraca, and Veyvondi.

Source: EMA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content